Susquehanna International Group, LLP Pro Qr Therapeutics N.V. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.64 - $2.24 $21,320 - $29,120	13,000 Added 53.28%	37,400 $68,000
Q2 2024 Aug 15, 2024	BUY	$1.65 - $2.39 $13,035 - $18,881	7,900 Added 47.88%	24,400 $40,000
Q1 2024 May 07, 2024	BUY	$1.89 - $2.85 $31,185 - $47,025	16,500 New	16,500 $37,000
Q2 2023 Aug 11, 2023	SELL	$1.62 - $2.32 $119,394 - $170,984	-73,700 Reduced 45.98%	86,600 $140,000
Q1 2023 May 16, 2023	BUY	$1.99 - $3.66 $208,950 - $384,300	105,000 Added 189.87%	160,300 $341,000
Q4 2022 Feb 14, 2023	BUY	$0.8 - $3.7 $31,520 - $145,780	39,400 Added 247.8%	55,300 $204,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $20,202 - $24,297	-27,300 Reduced 63.19%	15,900 $12,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $6,160 - $11,000	11,000 Added 34.16%	43,200 $34,000
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $28,980 - $270,158	32,200 New	32,200 $29,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $273M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.